Efficacy and Tolerability of MlC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine

Ali Amini Harandi *

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Farzad Ashrafi

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Mojgan Tabatabaei

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Askar Ghorbani

Tehran University of Medical Sciences, Tehran 13135-14117, Iran.

HamidReza Hatamian

Gylan University of Medical Sciences, Gylan 41625, Iran.

Hossein Pakdaman

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Manochehr Ilkhani

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Koroush Gharagozli

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Maziar Shojae

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Marjan Asadollahi

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Farshid Alaeddini

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

Seyed Kazem Hosseini

Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.

*Author to whom correspondence should be addressed.


Abstract

Aim: To evaluate the efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer disease (AD).
Study Design: This is an open-label pilot study.
Place and Duration of Study: It was conducted at three university referral centres in Iran from September 2009 until November 2011.
Methodology: One-hundred and twenty four outpatients with mild to moderate AD who had previously failed to tolerate or benefit from treatment with Rivastigmine for 6 months at a dose of 2 to 12 mg per day were switched to a MLC601 regimen of one capsule three times per day for up to 18 months. Outcome measures included adverse events (AEs), withdrawal rate, and changes in the Mini-Mental State Examination (MMSE) and the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements.
Results: Two patients were lost to follow up, and 122 patients completed the 18-month trial. The mean age of the participants was 65.3±6.4 years (range 54-82), and 77 (63.1%) of the participants were female. Improved cognitive function was observed in the first 6 months of the regimen (ADAS-cog=-3.1±10.1; MMSE=1.2±3.0), and the stabilisation of cognitive decline was observed over the remaining 12 months (ADAS-cog=-1.6±7.6; MMSE=0.8±4.2). AEs were predominantly gastrointestinal and occurred in 7.3% of patients.
Conclusions: MLC601 showed good tolerability and promising effects on cognitive function in AD patients during 18 months of treatment.

Keywords: Alzheimer disease, cholinesterase inhibitors, MLC601, NeuroAiD, neuroprotection, neuroregeneration


How to Cite

Harandi, A. A., Ashrafi, F., Tabatabaei, M., Ghorbani, A., Hatamian, H., Pakdaman, H., Ilkhani, M., Gharagozli, K., Shojae, M., Asadollahi, M., Alaeddini, F., & Hosseini, S. K. (2013). Efficacy and Tolerability of MlC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine. Journal of Advances in Medicine and Medical Research, 3(2), 341–350. https://doi.org/10.9734/BJMMR/2013/2537

Downloads

Download data is not yet available.